ADvantage Therapeutics is committed to addressing the urgent need for effective treatments for Alzheimer’s disease

Founded by a team of experts in neuroscience, drug development, and biotechnology, ADvantage Therapeutics is committed to addressing the urgent need for effective treatments for Alzheimer’s disease. The company is headquartered in the United States and collaborates with leading academic institutions, research organizations, and healthcare providers to accelerate its mission. ADvantage Therapeutics is focused on developing novel therapeutics that target the underlying mechanisms of Alzheimer’s disease. The company’s pipeline includes small molecules, biologics, and gene therapies designed to halt or slow the progression of the disease. These innovative treatments aim to improve cognitive function, enhance quality of life, and ultimately, alter the course of Alzheimer’s disease.